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Objective: Evidences indicate that the risk of stroke is increased in autoimmune
rheumatic diseases. This study aimed to investigate the incidence of stroke in patients
with systemic necrotizing vasculitis (SNV) using the national health database.
Methods: Data were obtained from the Korean National Claims database between 2010
and 2018 to identify incident SNV [anti-neutrophil cytoplasmic antibody-associated
vasculitis (AAV) and polyarteritis nodosa (PAN)] cases. The standardized incidence ratio
(SIR) and incidence rate ratio (IRR) were calculated to estimate the risk of stroke in patients
with SNV compared to the general population and among disease subgroups. Time-
dependent Cox’s regression analysis was performed to identify risk factors for stroke.
Results: Among 2644 incident SNV cases, 159 patients (6.0%) were affected by stroke.
The overall risk of stroke was significantly higher in patients with SNV compared to the
general population (SIR 8.42). Stroke event rates were the highest within the first year of
SNV diagnosis (67.3%). Among disease subgroups, patients with microscopic polyangiitis
(MPA) exhibited higher IRR compared to PAN (adjusted IRR 1.98). In Cox’s hazard
analysis, older age and MPA were associated with higher risk of stroke [hazard ratio (HR)
1.05 and 1.88], whereas the administration of cyclophosphamide, azathioprine/
mizoribine, methotrexate, and statins were protective in stroke (HR 0.26, 0.34, 0.49,
and 0.50, respectively).
Conclusion: A considerable number of SNV patients experienced stroke, especially in the
early phase of disease. Older age and MPA diagnosis were associated with elevated risk
of stroke, while the administration of immunosuppressive agents and statins was
beneficial in preventing stroke.
Keywords: systemic necrotizing vasculitis, anti-neutrophil cytoplasmic antibody-associated vasculitis, polyarteritis
nodosa, stroke, incidence, microscopic polyangiitisorg March 2021 | Volume 12 | Article 6299021
Ahn et al. Stroke in SNVINTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a rare systemic inflammatory disorder
causing necrotizing organ injury within small vessels, which
is typically associated with myeloperoxidase-ANCA or
proteinase 3-ANCA (1). AAV is divided into three distinct
diseases according to the clinical, laboratory, and histological
characteristics: microscopic polyangiitis (MPA), granulomatosis
with polyangiitis (GPA), and eosinophilic granulomatosis with
polyangiitis (EGPA) (2, 3). AAV can affect any organ of the
body and various clinical symptoms occur depending on the
organs affected. On the other hand, polyarteritis nodosa
(PAN), which is classified as systemic vasculitis involving the
medium-sized vessels, also causes necrotizing vasculitis (4).
Owing to the pathologic similarities, AAV and PAN are
traditionally considered to comprise a group of systemic
necrotizing vasculitis (SNV) (5).
Stroke is defined as a medical condition of acute and focal
functional impairment of the brain, retina, or spinal cord; it is
associated with significant mortality and disability (6, 7). Stroke is
generally divided into hemorrhagic and ischemic subtypes;
ischemic stroke is the most common type, accounting for up to
70% of cases (8, 9). Several common risk factors for the occurrence
of stroke, such as older age, sex, hypertension, dyslipidemia,
diabetes mellitus, atrial fibrillation, and smoking, have been
suggested (9, 10). Besides, a growing body of evidence has
suggested that chronic inflammation and high degree of
inflammation are crucial factors associated with increased
vascular thrombosis in autoimmune rheumatic diseases by
triggering the coagulation cascade (11, 12). In this context,
previous studies have reported an increased risk of stroke in
patients with large vessel vasculitis, such as Takayasu arteritis
(TA) and giant cell arteritis (GCA). A retrospective study by
Hwang et al. demonstrated that more than 10% of patients with
TA experienced ischemic stroke (13), and Nesher et al. showed
that cranial ischemic complications are common in patients with
GCA, implying that patients with systemic vasculitis are at a high
risk of developing stroke (14). Mechanistically, the development of
atherosclerotic lesions is considered an important cause of stroke
(15). Similarly, in the pathogenesis of SNV, subclinical
atherosclerosis is accelerated as a consequence of systemic and
localized inflammation and deterioration of helper T (Th) cell
balance (16). Based on these findings, even though it is possible
that the risk of stroke is increased in patients with SNV, the
incidence of stroke in patients with SNV has not been investigated
in detail. Therefore, this study was conducted to investigate the
incidence of stroke in SNV using a nationwide database.MATERIALS AND METHODS
Data Extraction From the Health Insurance
and Review Agency Database
The principal diagnosis and comorbidities [based on International
Classification of Diseases (ICD)-10 codes], clinical information
(age, sex, geographic area), and the administered medication of theFrontiers in Immunology | www.frontiersin.org 2patients were obtained from the Health Insurance and Review
Agency (HIRA) database. The HIRA database is a nationwide
claims data repository that includes information of medical service
utilization of an individual, which is comprised of: general and
providers’ information, the use of healthcare services, diagnosis,
and the data of drug prescription (17). This information is
submitted by medical institutions to the Korean government in
order to request monetary reimbursement and is integrated and
recorded in the HIRA database. A schematic figure depicting the
generation and utilization of HIRA data is described in
Supplementary Figure 1. By using this database, it is possible to
access the information of the entire population (nearly 50 million
patients) that is enrolled in the National Health Insurance System
of Korea (18).
To identify SNV patients, the respective ICD-10 codes for
MPA (M31.7), GPA (M31.3), EGPA (M30.1), and PAN (M30.0)
were used. Patients were diagnosed with SNV when they
were first registered with the corresponding ICD-10 codes
for AAV or PAN in a general or tertiary hospital and were
prescribed with glucocorticoids (betamethasone, dexamethasone,
methylprednisolone, prednisone, prednisolone, hydrocortisone,
triamcinolone, budesonide, and deflazacort) during the follow-
up period (19). The date on which the diagnosis of SNV was first
registered in the HIRA database was defined as the index date, and
the medications of immunosuppressive agents (glucocorticoids,
cyclophosphamide, rituximab, azathioprine/mizoribine, and
methotrexate), antiplatelet agents (aspirin, clopidogrel), and
statins that were prescribed after the diagnosis of SNV were
also counted.
The entire data of the study population were first extracted
from the HIRA database between January 2008 and December
2018, and a 2-year washout period was given to exclude patients
with the diagnosis of SNV prior to the study period. This study
was approved by the ethics review board of Severance Hospital,
and the requirement to obtain informed consent was waived
owing to the retrospective study design (IRB approval number:
4-2019-0177).
Identification of SNV Cases With Stroke
and Comorbidities
SNV patients with incident stroke were defined as those admitted
to a hospital and newly registered with ICD-10 codes for stroke
(I60-I64) in the HIRA database after the diagnosis of SNV (20,
21). The follow-up duration was defined as the index date of SNV
diagnosis to the date of stroke occurrence in patients with stroke
and until the last follow-up date for patients without stroke.
Comorbidities for stroke searched included hypertension (I10-
15), diabetes mellitus (E10-14), atrial fibrillation/flutter (I48),
and dyslipidemia (E78) within 1 year of the index date of
SNV diagnosis.
Estimation of Stroke Incidence in Patients
With AAV Using In-Hospital Data
For internal validation purposes, the incidence of stroke was
estimated by reviewing the medical records of 193 patients first
diagnosed with AAV in Severance Hospital between December
2000 and December 2018. All patients were classified into AAVMarch 2021 | Volume 12 | Article 629902
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algorithm for AAV and the descriptions provided by the 2012
Chapel Hill Consensus Conference. Demographic data,
including age, sex, body mass index, and ANCA serotypes, and
laboratory data, as well as the diagnosis and stroke subtypes were
investigated. Birmingham Vasculitis Activity Score (version 3)
(BVAS) and Five Factor Score (2009) were calculated as
previously described (22, 23).
Statistical Analysis
Continuous and categorical variables are presented as mean ±
standard deviation and frequencies (percentage), respectively,
and were compared using Student’s t-test and the chi-square test.
To compare the incidence of stroke between SNV patients and
the general population, the standardized incidence ratio (SIR)
adjusted by age was calculated using data from the 2006 Korean
Center for Disease Control & Prevention Report for the general
population (24). The risk of stroke among the disease subgroups
of SNV was compared by calculating age- and sex- adjusted
incidence rate ratio (IRR) and 95% confidence interval (CI) using
Poisson regression analysis with an offset for person-years. The
cumulative incidence of stroke was calculated using the Kaplan–
Meier method, and differences among disease subgroups were
determined by the log-rank test. Factors associated with the
incidence of stroke were investigated using Cox’s regression
model by including medication usage as time-dependentFrontiers in Immunology | www.frontiersin.org 3covariates. SAS Enterprise Guide version 9.4 (SAS Institute
Inc., Cary, NC) was used for all statistical analyses, and a
p-value < 0.05 was considered statistically significant.RESULTS
Baseline Characteristics of SNV Patients
With and Without Stroke
A total of 2984 AAV and PAN cases were found in the HIRA
database between 2010 and 2018. Of these, 340 patients who had
been previously diagnosed with stoke (I60-I64) were excluded. In
the remaining 2644, 159 (6.0%) patients were identified to have
stroke after the diagnosis of SNV was established (Figure 1). The
mean follow-up duration was 1.2 years for patients with stroke
and 3.4 years for patients without stroke. When comparing the
clinical characteristics between patients with stroke and those
without, the age at diagnosis was higher (mean age 66.50 and
56.02, p<0.001) in patients with stroke. In addition, the diagnosis
of MPA was more frequent in patients with stroke than in those
without (49.7% vs. 33.2%, p<0.001). Regarding comorbidities,
hypertension, diabetes mellitus, and dyslipidemia were more
common in SNV patients with stroke, whereas the proportion
of patients administered glucocorticoids ≥ 1 year, azathioprine/
mizoribine, methotrexate, and statins was significantly higher inFIGURE 1 | Selection of the study population from the HIRA database. HIRA, Health Insurance and Review Agency; SNV, systemic necrotizing vasculitis;
MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa.March 2021 | Volume 12 | Article 629902
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present regarding baseline clinical characteristics of SNV
subgroups. In particular, patients with MPA were older and
the proportion of patients with comorbidities at baseline was
higher in MPA compared to other subgroups of SNV
(Supplementary Table 1).
Risk of Stroke in SNV Patients Compared
to the General Population
The age distribution of SNV patients when they experienced
stroke is shown in Figure 2. The total number of stroke events
increased with age, and the peak was observed at 65-74 years
(n=59). In those aged ≥75 years, it was slightly lower than that in
patients aged 65-74 years (n=52).
Compared to the general population, the overall risk of stroke
was significantly higher in patients with SNV (SIR 8.42, 95% CIFrontiers in Immunology | www.frontiersin.org 47.16-9.84); this was found to be the same in MPA, GPA, EGPA,
and PAN. The overall risk of stroke was highest in patients with
MPA (SIR 16.26, 95% CI 12.87-20.26). Moreover, when patients
were divided according to age, such as age ≤ 54 years, age 55-74
years, and age ≥ 75 years, the SIR for stroke was highest in
patients aged ≤ 54 years; this decreased as the age of patients
increased (Supplementary Figure 2).
Type and Incidence of Stroke After SNV
Diagnosis
Among the 159 patients with stroke, cerebral infarction [I63]
(n=115) was the most common stroke subtype, accounting for
72.3% of patients. Furthermore, the incidence of stroke was
highest in patients with MPA (n=79, 49.7%), followed by those
with EGPA, GPA, and PAN. Regarding the time for stroke
occurrence after SNV diagnosis, 107 (67.3%) patients developedTABLE 1 | Baseline clinical characteristics of SNV patients with stroke and those without stroke.
Total, n=2644 Patients with stroke, n=159 Patients without stroke, n=2485 p-value
Age at diagnosis (years) 56.65 ± 16.84 66.50 ± 13.34 56.02 ± 16.85 <0.001
≤54 1052 (39.8) 28 (17.6) 1024 (41.2) <0.001
55-74 1225 (46.3) 84 (52.8) 1141 (45.9)
≥75 367 (13.9) 47 (29.6) 320 (12.9)
Sex, n (%) 0.885
Male 1191 (45.1) 73 (45.9) 1118 (45.0)
Female 1453 (54.9) 86 (54.1) 1367 (55.0)
Diagnosis [ICD-10 code], n (%) <0.001
MPA (M31.7) 904 (34.2) 79 (49.7) 825 (33.2)
GPA (M31.3) 606 (22.9) 31 (19.5) 575 (23.1)
EGPA (M30.1) 593 (22.4) 32 (20.1) 561 (22.6)
PAN (M30.0) 541 (20.5) 17 (10.7) 524 (21.1)
Geographic Area, n (%) 0.219
Seoul 1197 (45.3) 64 (40.3) 1133 (45.6)
Outside Seoul 1447 (54.7) 95 (59.7) 1352 (54.4)
Comorbidities [ICD-10 code]
Hypertension [I10-15] <0.001
No 1477 (55.9) 60 (37.7) 1417 (57.0)
Yes 1167 (44.1) 99 (62.3) 1068 (43.0)
Diabetes mellitus [E10-14] <0.001
No 1813 (68.6) 87 (54.7) 1726 (69.5)
Yes 831 (31.4) 72 (45.3) 759 (30.5)
Atrial fibrillation/flutter [I48] 0.299
No 2576 (97.4) 153 (96.2) 2423 (97.5)
Yes 68 (2.6) 6 (3.8) 62 (2.5)
Dyslipidemia [E78] 0.005
No 1409 (53.3) 67 (42.1) 1342 (54.0)
Yes 1235 (46.7) 92 (57.9) 1143 (46.0)
Medication usage, n (%)
Immunosuppressive agents
Glucocorticoid usage ≥ 1
year
1225 (46.3) 31 (19.5) 1194 (48.1) <0.001
Cyclophosphamide 1124 (42.5) 62 (39.0) 1062 (42.7) 0.399
Rituximab 252 (9.5) 8 (5.0) 244 (9.8) 0.064
Azathioprine/mizoribine 991 (37.5) 29 (18.2) 962 (38.7) <0.001
Methotrexate 431 (16.3) 8 (5.0) 423 (17.0) <0.001
Antiplatelet agents
Aspirin 608 (23.0) 32 (20.1) 576 (23.2) 0.430
Clopidogrel 232 (8.8) 10 (6.3) 222 (8.9) 0.318
Statins 996 (37.7) 45 (28.3) 951 (38.3) 0.015March 2021 | Volume 12 | ArticleValues are expressed as mean (standard deviation) or number (percentages).
SNV, systemic necrotizing vasculitis; ICD, International classification of diseases; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis
with polyangiitis; PAN, polyarteritis nodosa.629902
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of stroke gradually decreased over time after SNV was diagnosed,
showing a similar pattern in all disease subgroups (Table 2).
When we compared the cumulative incidence rate of stroke
according to disease subgroups, patients with MPA, GPA, and
EGPA had a higher incidence of stroke than those with PAN (all
p<0.001). The cumulative incidence rate of stroke was highest in
patients with MPA; it was 6.79 (95% CI 5.06-8.52), 10.02 (95% CI
7.65-12.39), and 19.46 (95% CI 11.56-27.36) at 1, 4, and 9 years,
respectively (Figure 3). On comparing the incidence rates among
the SNV subgroups, MPA patients exhibited the highest risk
(crude IRR 4.85 vs. PAN, 95% CI 2.87-8.19); the risk of stroke
was consistently higher in MPA patients than in PAN even after
adjusting for age and sex (adjusted IRR 1.98, 95% CI 1.15-3.40)
(Supplementary Table 2).
Risk Factors Associated With the
Occurrence of Stroke in SNV
In Cox’s hazard regression analysis, older age, the diagnosis of
MPA, GPA, and EGPA, and comorbidities of hypertension,FIGURE 2 | Age distribution of SNV patients on stroke occurrence. The incidence of stroke events was estimated by dividing age into 10-year intervals. SNV,
systemic necrotizing vasculitis; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN,
polyarteritis nodosa.TABLE 2 | Type and incidence of stroke events after SNV diagnosis.
Type of stroke Total MPA GPA EGPA PAN
Subarachnoid hemorrhage [I60] 14 (8.8) 7 (8.9) 3 (9.7) 4 (12.5) 0 (0.0)
Intracerebral hemorrhage [I61] 21 (13.2) 11 (13.9) 2 (6.5) 6 (18.7) 2 (11.8)
Other non-traumatic intracranial hemorrhage [I62] 6 (3.8) 2 (2.5) 1 (3.2) 2 (6.3) 1 (5.9)
Cerebral infarction [I63] 115 (72.3) 57 (72.1) 25 (80.6) 20 (62.5) 13 (76.5)
Stroke, not specified as hemorrhage or infarction [I64] 3 (1.9) 2 (2.5) 0 (0.0) 0 (0.0) 1 (5.9)
Total 159 (100.0) 79 (100.0) 31 (100.0) 32 (100.0) 17 (100.0)
Time of stroke occurrence after SNV diagnosis
<1 year 107 (67.3) 56 (70.9) 19 (61.3) 22 (68.8) 10 (58.8)
1-3 years 29 (18.2) 13 (16.5) 6 (19.4) 6 (18.8) 4 (23.5)
>3 years 23 (14.5) 10 (12.7) 6 (19.4) 4 (12.5) 3 (17.7)Frontiers in Immunology | www.frontiersin.org 5 March 2021 | Volume 12 | ArticValues are expressed in number (percentages).
SNV, systemic necrotizing vasculitis; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa.FIGURE 3 | Cumulative incidence rate of stroke according to SNV
subgroups. Among the SNV subgroups, the cumulative incidence rate of
stroke was found to be highest in MPA. SNV, systemic necrotizing vasculitis;
MPA, microscopic polyangiitis; PAN, polyarteritis nodosa; GPA, granulomatosis
with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis.le 629902
Ahn et al. Stroke in SNVdiabetes mellitus, and dyslipidemia were associated with
increased risk of stroke in the unadjusted analysis. On the
other hand, the administration of cyclophosphamide,
azathioprine/mizoribine, and methotrexate were inversely
associated with stroke occurrence. However, in an adjusted
analysis, age at diagnosis [hazard ratio (HR) 1.05, 95% CI 1.03-
1.06, p<0.001], the diagnosis of MPA (HR 1.88, 95% CI 1.08-3.26,
p=0.025), and cyclophosphamide (HR 0.26, 95% CI 0.14-0.49,
p<0.001), azathioprine/mizoribine (HR 0.34, 95% CI 0.18-
0.65, p=0.001), methotrexate (HR 0.49, 95% CI 0.24-0.99,
p=0.046), and statin (HR 0.50, 95% CI 0.32-0.80, p=0.004)
administration were independent risk factors of stroke (Table 3).
Clinical Characteristics of AAV Patients
With Stroke in the Hospital Database
We reviewed the medical records of patients diagnosed with
AAV in the hospital and who experienced stroke. Among the 193Frontiers in Immunology | www.frontiersin.org 6patients included, 12 (6.2%) experienced stroke during the
follow-up. The baseline age and BVAS at diagnosis among
patients with stroke were 64.5 years and 15.6, respectively, and
the follow-up duration was 18.7 months. MPA (58.3%) was the
most common diagnosis, followed by GPA (33.3%) and EGPA
(8.3%). The disease duration after AAV diagnosis was less than 1
year in 9 (75.0%) patients, and ischemic subtype (91.7%)
accounted for the majority of stroke events (Table 4).DISCUSSION
Even though the incidence of stroke is increased in patients with
autoimmune rheumatic diseases (12), in patients with SNV, the
incidence is unclear. In this study, using a nationwide claims
database, we showed that a considerable number of patients with
SNV (6.0%) are affected with stroke after disease diagnosis andTABLE 3 | Factors associated with the risk of stroke in SNV patients.
Crude hazard ratio Adjusted hazard ratio
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age at diagnosis 1.06 (1.05-1.07) <0.001 1.05 (1.03-1.06) <0.001
Sex
Male 1.08 (0.79-1.47) 0.646 0.99 (0.73-1.37) 0.977
Female 1.00 (ref) 1.00 (ref)
Diagnosis
MPA 3.69 (2.18-6.25) <0.001 1.88 (1.08-3.26) 0.025
GPA 1.88 (1.04-3.41) 0.036 1.20 (0.65-2.19) 0.559
EGPA 1.89 (1.05-3.40) 0.035 1.25 (0.69-2.27) 0.460
PAN 1.00 (ref) 1.00 (ref)
Geographic area
Seoul 1.00 (ref) 1.00 (ref)
Outside Seoul 1.26 (0.92-1.73) 0.149 1.25 (0.90-1.72) 0.179
Comorbidities
Hypertension
No 1.00 (ref) 1.00 (ref)
Yes 2.42 (1.76-3.34) <0.001 1.30 (0.91-1.87) 0.151
Diabetes mellitus
No 1.00 (ref) 1.00 (ref)
Yes 2.02 (1.48-2.76) <0.001 1.26 (0.91-1.77) 0.170
Atrial fibrillation/flutter
No 1.00 (ref) 1.00 (ref)
Yes 1.59 (0.71-3.60) 0.263 0.95 (0.43-2.11) 0.898
Dyslipidemia
No 1.00 (ref) 1.00 (ref)
Yes 1.83 (1.33-2.51) <0.001 1.29 (0.91-1.83) 0.149
Medication usage†
Immunosuppressive agents
Glucocorticoid usage ≥ 1
year
0.82 (0.47-1.41) 0.467 1.15 (0.65-2.02) 0.628
Cyclophosphamide 0.34 (0.18-0.63) <0.001 0.26 (0.14-0.49) <0.001
Rituximab 0.21 (0.01-3.35) 0.266 0.12 (0.01-1.97) 0.136
Azathioprine/mizoribine 0.36 (0.19-0.69) 0.002 0.34 (0.18-0.65) 0.001
Methotrexate 0.40 (0.20-0.82) 0.012 0.49 (0.24-0.99) 0.046
Antiplatelet agents
Aspirin 1.33 (0.82-2.14) 0.249 1.20 (0.73-1.98) 0.480
Clopidogrel 1.56 (0.73-3.34) 0.250 1.12 (0.52-2.42) 0.767
Statins 0.77 (0.50-1.19) 0.243 0.50 (0.32-0.80) 0.004March 2021 | Volume 12 | Article†Medication usage was selected as time-dependent covariates.
SNV, systemic necrotizing vasculitis; CI, confidence interval; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis;
PAN, polyarteritis nodosa.629902
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Frontiers in Immunology | www.frontiersin.org 7the risk of stroke was significantly higher than that among the
general population (SIR 8.42). Most stroke events in patients
with SNV presented as ischemic subtypes, similar to the finding
in the general population. In addition, among the disease
subgroups, patients with MPA were most commonly affected
with stroke. Importantly, these findings were reproduced
through the in-hospital data, which revealed comparable
results. Finally, the administration of immunosuppressive
agents and statins showed clinical benefits in the prevention
of stroke.
The risk of stroke is increased in autoimmune rheumatic
diseases, such as rheumatoid arthritis and systemic lupus
erythematosus (25). Likewise, the risk of stroke was
significantly higher in SNV patients than in the general
population. Even though the exact cause of this finding is
unclear, the elevated risk of stroke may be attributable to the
development of premature atherosclerosis in chronic
inflammatory diseases (26). Otherwise, the acceleration of
atherosclerosis can be also facilitated by direct vascular
involvement in inflammation, which is mediated by antibodies
or immune complexes (27). Additionally, the overproduction of
proinflammatory cytokines, chemokines, and coagulation
proteins may promote endothelial dysfunction and activation,
resulting in atherosclerosis promotion (28). Finally, the
activation of macrophages in autoimmune rheumatic diseases,
which plays an important role in the progression of
atherosclerotic lesions and the formation of foam cells, could
be relevant to increased risk of stroke in SNV (29).
Age is an important factor contributing to stroke in the
general population (9). According to the 2006 data from the
Korean Center for Disease Control & Prevention Report,
the incidence of stroke increases with age in the general
population (21). Consistently, the baseline age of SNV patients
with stroke was 66.5 years, which was approximately 10 years
higher than that of SNV patients without stroke. Moreover, in
patients with SNV, the incidence of stroke was much higher than
that of the normal population of the same age group, implying
that age and disease itself are independent risk factors of stroke.
Collectively, it could be suggested that careful observation for the
occurrence of stroke and the implementation of preventive
measures of stroke are required in patients with SNV.
Several studies have investigated the risk of stroke in patients
with SNV, but with inconsistent results. Although Mourguet
et al. reported that patients with GPA and MPA experienced
ischemic stroke four times more frequently than the general
population, the observations by Berti et al. revealed that stroke
incidence was eight times higher in patients with AAV than in
the general population (30, 31). On the contrary, the risk of
stroke was not apparent in patients with GPA (32). The
discordant results could be related to the difference in disease
subgroups analyzed, the number of patients included, and the
type of stroke investigated. The results from our study are
noteworthy as we observed the increased risk of stroke in SNV
using a largest dataset, and the incidence of stroke in Asia has not
been described in the literature. Nevertheless, given that
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Ahn et al. Stroke in SNVof vasculitis and that racial and ethnic disparity should be
considered in the incidence of stroke (33, 34), further research
is necessary to validate the findings from our study.
Intriguingly, the observations from our study have
demonstrated that 67.3% of patients have experienced stroke
within 1 year of diagnosis, and the incidence of stroke gradually
decrease during the disease course, which was found to be similar
to the data from the United Kingdom (35). In addition, in a time-
dependent Cox’s hazards regression analysis, treatment with
immunosuppressive agents of cyclophosphamide, azathioprine/
mizoribine, and methotrexate was inversely correlated with the
occurrence of stroke. Of note, even though statistical significance
was not demonstrated, the adjusted HR of developing stroke in
patients treated with rituximab, which is now considered as a
first line therapy for AAV, was found to be remarkably low.
Owing to the fact that patients generally have the highest disease
activity on initial presentation, and the reason to prescribe
immunosuppressive drugs are used to maintain adequate
disease control, it could be suggested that tight disease control
is essential to reduce the occurrence of stroke in patients with
SNV. This assumption could be supported by the analysis of in-
hospital data, which showed that patients who developed stroke
in the early disease phase generally had a higher disease activity
(BVAS) and inflammatory markers of erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP). Nonetheless, given that
patients with SNV are usually followed-up more shortly after
initial diagnosis, a possibility of detection bias from closer follow-
up could not be excluded.
Among the disease subgroups, the incidence of stroke was the
highest in MPA and lowest in PAN, and Cox’s hazards regression
analysis revealed that the risk of stroke was increased in MPA
compared to PAN. Although the direct cause of the difference of
stroke according to disease subgroups is unknown, previous
reports have described that stroke is known to be a relatively
rare complication of PAN (36). Moreover, the higher incidence
of stroke, especially in MPA, could be associated with the fact
that MPA is an aggressive disease with severe renal and
pulmonary symptoms and has a poor prognosis compared to
other SNV subtypes (37, 38). Accordingly, considering the high
inflammatory burden in MPA, it could be speculated that the
occurrence of stroke is higher in MPA than in other disease
subtypes. Meanwhile, it is reported that patients with MPA in
South Korea and Japan most often manifest with renal
involvement (39, 40), and a characteristic pathologic lesion in
renal biopsy in MPA is rapidly progressive glomerulonephritis
(5, 41). Based on the fact that impaired renal function is also a
potential risk factor of stroke, the higher incidence of renal
involvement in MPA could be associated with the increased risk
of stroke (42).
Comorbidities that could influence in the occurrence of
stroke include hypertension, diabetes mellitus, dyslipidemia,
and atrial fibrillation (24). In this study, no significant
association between the comorbidities investigated and stroke
was observed in Cox’s hazards regression analysis. Surprisingly,
we found that the use of statins was associated with reduced risk
of stroke. Several different effects of statins could be considered inFrontiers in Immunology | www.frontiersin.org 8attenuating the risk of stroke in SNV. First, statins are effective in
preventing atherosclerosis by reducing circulating low-density
lipoproteins, and the attenuation of atherosclerotic lesions by
statins could lead to a decreased incidence of stroke (43). Second,
statins are able to provide non-lipid dependent vascular
protective effects. Statins could maintain endothelial function
through upregulation of endothelial nitric oxide synthase or
antioxidant defense systems (44). Furthermore, statin inhibits
recruitment, adhesion, and migration of inflammatory cells to
help stabilize the inflamed vasculature (45). Third, statins could
also provide immunomodulatory effects by suppressing T cell
activation, which plays a crucial role in vascular inflammatory
disorders (46). Statins could act as inhibitors of MHC-II-
mediated T-cell activation by influencing MHC-II expression
through IFN-g and suppress Th1 responses (47). Furthermore, it
was also shown that statins affect Th17 cell differentiation and
directly inhibit IL-17 production in CD4+ cells (48). Finally, it
was shown that treatment with statin could hamper macrophage
activation, as well as reducing the expression of inflammatory
cytokines and chemokines (45, 49). Therefore, the preventive
effect of statins in stroke could be also mediated by controlling
vascular dysfunction and providing immunomodulatory effects.
Although this is the first study to evaluate the risk of stroke in
patients with SNV using a nationwide database, several
drawbacks are present in this study. First, due to the inherent
limitations of the HIRA data, we failed to analyze the effect of
common modifiable risk factors for stroke, such as smoking,
alcohol, and body mass index. Second, besides age, sex, and
medication usage, other clinical data, such as disease activity and
organ involvement, were not identifiable through the HIRA
database. In addition, laboratory data regarding cholesterol
profiles and its changes, as well as ANCA serotypes and
inflammatory markers of ESR and CRP, were also not
accessible. Third, even though a Cox’s hazard regression
analysis was performed to identify risk factors associated with
stroke in SNV, large disparities of baseline characteristics were
present between the disease subgroups. Fourth, the risk of stroke
in SNV compared to the general population was assessed using a
nationwide report as a reference, and the comorbidities of
patients were investigated only by using the ICD-10 codes.
Thus, the relationship between comorbidities in SNV and
stroke should be better verified in future studies. Fifth, in this
study, both the occurrence of ischemic and hemorrhagic stroke
was analyzed as stroke event. However, as the underlying
pathogenesis of ischemic and hemorrhagic stroke is different,
the precise mechanism leading to increased stroke in SNV
remains to be further investigated. Finally, owing to the
relatively small number of patients with stroke and those
treated with rituximab, the effect of rituximab therapy in
reducing stroke might not have reached statistical significance.CONCLUSION
In conclusion, the results of our study demonstrated that the
overall incidence of stroke is elevated in patients with SNV,March 2021 | Volume 12 | Article 629902
Ahn et al. Stroke in SNVespecially in the early phase of disease diagnosis. In addition,
differences were found regarding the incidence of stroke
according to disease subgroups. Moreover, the use of
immunosuppressive agents and statins was associated with
decreased risk of stroke. Our results indicate that special
attention should be given regarding the incidence of stroke in
patients with SNV, and adequate disease control and use of
statins could be beneficial in minimizing the risk of stroke.DATA AVAILABILITY STATEMENT
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Associated with Major Cardiovascular Events in Patients with Systemic
Necrotizing Vasculitides: Results of a Longterm Followup Study.
J Rheumatol (2014) 41:723–9. doi: 10.3899/jrheum.130882
17. Kim JA, Yoon S, Kim LY, Kim DS. Towards Actualizing the Value Potential of
Korea Health Insurance Review and Assessment (HIRA) Data as a Resource
for Health Research: Strengths, Limitations, Applications, and Strategies for
Optimal Use of HIRA Data. J Korean Med Sci (2017) 32:718–28. doi: 10.3346/
jkms.2017.32.5.718
18. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review
and Assessment Service National Patient Samples. Epidemiol Health (2014)
36:e2014008. doi: 10.4178/epih/e2014008
19. Ahn SS, Han M, Yoo J, Jung SM, Song JJ, Park YB, et al. Risk of Cancers in
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from the
Korea National Health Insurance Claims Database 2010-2018. J Clin Med
(2019) 8(11):1871. doi: 10.3390/jcm8111871March 2021 | Volume 12 | Article 629902
Ahn et al. Stroke in SNV20. Woodfield R, Grant I, Sudlow CL. Accuracy of Electronic Health Record Data
for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A
Systematic Review from the UK Biobank Stroke Outcomes Group. PloS One
(2015) 10:e0140533. doi: 10.1371/journal.pone.0140533
21. Hong KS, Bang OY, Kang DW, Yu KH, Bae HJ, Lee JS, et al. Stroke statistics in
Korea: part IEpidemiology and risk factors: a report from the korean stroke
society and clinical research center for stroke. J Stroke (2013) 15:2–20. doi:
10.5853/jos.2013.15.1.2
22. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al.
Modification and validation of the Birmingham Vasculitis Activity
Score (version 3). Ann Rheum Dis (2009) 68:1827–32. doi: 10.1136/
ard.2008.101279
23. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The
Five-Factor Score revisited: assessment of prognoses of systemic necrotizing
vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
Medicine (2011) 90:19–27. doi: 10.1097/MD.0b013e318205a4c6
24. Kim JY, Kang K, Kang J, Koo J, Kim DH, Kim BJ, et al. Executive Summary of
Stroke Statistics in Korea 2018: A Report from the Epidemiology Research
Council of the Korean Stroke Society. J Stroke (2019) 21:42–59. doi: 10.5853/
jos.2018.03125
25. Liou TH, Huang SW, Lin JW, Chang YS, Wu CW, Lin HW. Risk of stroke in
patients with rheumatism: a nationwide longitudinal population-based study.
Sci Rep (2014) 4:5110. doi: 10.1038/srep05110
26. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune
diseases. Nat Clin Pract Rheumatol (2006) 2:99–106. doi: 10.1038/
ncprheum0092
27. Burut DF, Karim Y, Ferns GA. The role of immune complexes in
atherogenesis. Angiology (2010) 61:679–89. doi: 10.1177/0003319710366124
28. Ramji DP, Davies TS. Cytokines in atherosclerosis: Key players in all stages of
disease and promising therapeutic targets. Cytokine Growth Factor Rev (2015)
26:673–85. doi: 10.1016/j.cytogfr.2015.04.003
29. Bobryshev YV, Ivanova EA, Chistiakov DA, Nikiforov NG, Orekhov AN.
Macrophages and Their Role in Atherosclerosis: Pathophysiology and
Transcriptome Analysis. BioMed Res Int (2016) 2016:9582430. doi: 10.1155/
2016/9582430
30. Mourguet M, Chauveau D, Faguer S, Ruidavets JB, Bejot Y, Ribes D, et al.
Increased ischemic stroke, acute coronary artery disease and mortality in
patients with granulomatosis with polyangiitis and microscopic polyangiitis.
J Autoimmun (2019) 96:134–41. doi: 10.1016/j.jaut.2018.09.004
31. Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of
Cardiovascular Disease and Venous Thromboembolism Among Patients
With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based
Cohort Study. Mayo Clin Proc (2018) 93:597–606. doi: 10.1016/j.mayocp.
2018.02.010
32. Avina-Zubieta JA, Mai A, Amiri N, Dehghan N, Ann Tan J,
Sayre EC, et al. Risk of Myocardial Infarction and Stroke in Patients
With Granulomatosis With Polyangiitis (Wegener’s): A Population-Based
Study. Arthritis Rheumatol (Hoboken NJ) (2016) 68:2752–9. doi: 10.1002/
art.39762
33. Gutierrez J, Williams OA. A decade of racial and ethnic stroke disparities in
the United States. Neurology (2014) 82:1080–2. doi: 10.1212/WNL.
0000000000000237
34. Naidu G, Misra DP, Rathi M, Sharma A. Is granulomatosis with polyangiitis
in Asia different from the West? Int J Rheum Dis (2019) 22 Suppl 1:90–4. doi:
10.1111/1756-185X.13398Frontiers in Immunology | www.frontiersin.org 1035. Kang A, Antonelou M,Wong NL, Tanna A, Arulkumaran N, Tam FWK, et al.
High Incidence of Arterial and Venous Thrombosis in Antineutrophil
Cytoplasmic Antibody-associated Vasculitis. J Rheumatol (2019) 46:285–93.
doi: 10.3899/jrheum.170896
36. Reichart MD, Bogousslavsky J, Janzer RC. Early lacunar strokes complicating
polyarteritis nodosa: thrombotic microangiopathy. Neurology (2000) 54:883–
9. doi: 10.1212/WNL.54.4.883
37. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis:
clinical features and mortality. QJM (2005) 98:97–111. doi: 10.1093/qjmed/
hci015
38. Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clinics North Am
(2010) 36:545–58. doi: 10.1016/j.rdc.2010.04.003
39. Yoo J, Kim HJ, Ahn SS, Jung SM, Song JJ, Park YB, et al. Clinical and
prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and
ANCA-negative vasculitis. Clin Exp Rheumatol (2017) 35 Suppl 103:111–8.
40. Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al.
Classification and characteristics of Japanese patients with antineutrophil
cytoplasmic antibody-associated vasculitis in a nationwide, prospective,
inception cohort study. Arthritis Res Ther (2014) 16:R101. doi: 10.1186/ar4550
41. Syed R, Rehman A, Valecha G, El-Sayegh S. Pauci-Immune Crescentic
Glomerulonephritis: An ANCA-Associated Vasculitis. BioMed Res Int
(2015) 2015:402826. doi: 10.1155/2015/402826
42. Dad T, Weiner DE. Stroke and Chronic Kidney Disease: Epidemiology,
Pathogenesis, and Management Across Kidney Disease Stages. Semin
Nephrol (2015) 35:311–22. doi: 10.1016/j.semnephrol.2015.06.003
43. Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends
Cardiovasc Med (2019) 29:451–5. doi: 10.1016/j.tcm.2019.01.001
44. Beckman JA, Creager MA. The nonlipid effects of statins on endothelial
function. Trends Cardiovasc Med (2006) 16:156–62. doi: 10.1016/
j.tcm.2006.03.003
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